// App-Quantinova.ai

1985 : First Line Therapy With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem Cell Transplant

Researchers

Presenter

  • Giovanni Palladini

Principal Investigators

  • Paolo Milani

  • Marta Vidus Rosin

  • Andrea Foli

  • Giampaolo Merlini

Medical Centers

  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Department of Molecular Medicine, Pavia, Italy

  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Deep vein thrombosis

  • Congestive heart failure

  • Cardiac amyloidosis

  • Venous thrombosis

  • AL Amyloidosis

  • Renal insufficiency

  • Amyloid disease

  • Albuminuria

Biomarkers

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved